Qin Chunmeng, Sun Mei, Lv Feng, Du Dan, Li Wenjun, Liu Songqing
Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
College of Pharmacy, Chongqing Medical University, Chongqing, 400016, China.
Curr Comput Aided Drug Des. 2025;21(3):316-332. doi: 10.2174/0115734099297600240523105601.
The clinical use of doxorubicin (DOX), an anthracycline antibiotic with broad-spectrum applications against various malignant tumors, is limited by doxorubicininduced cardiotoxicity (DIC). Eriodictyol (ERD) has shown cardioprotective effects, but the mechanism of its protective effect on DIC remains unknown.
This study aimed to explore the potential mechanisms by which ERD confers protection against DIC.
ERD and DIC targets were identified from the TCMSP, PharmMaper, SwissTargetPrediction, TargetNet, BATMAN, GeneCards, and PharmGKB databases. Differential gene expression data between DIC and normal tissues were extracted from the GEO database. A protein‒ protein interaction (PPI) network of the intersecting ERD-DIC targets was constructed using the STRING platform and visualized with Cytoscape 3.10.0 software. Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for ERD-DIC cross-targets were conducted. Validation included molecular docking with AutoDock Tools software and molecular dynamics simulations with Gromacs 2019.6 software.
Network pharmacology analysis revealed 43 intersecting ERD-DIC targets, including 6 key targets. GO functional enrichment analysis indicated that the intersecting targets were enriched in 550 biological processes, 45 cell components, and 41 molecular functions. KEGG pathway enrichment analysis identified 114 enriched signaling pathways. Molecular docking revealed a strong binding affinity between ERD and 6 key targets, as well as multiple targets within the ROS pathway. Molecular dynamics simulations indicated that ERD has favorable binding with 3 crucial targets.
The systematic network pharmacology analysis suggests that ERD may mitigate DIC through multiple targets and pathways, with the ROS pathway potentially playing a crucial role. These findings provide a reference for foundational research and clinical applications of ERD in treating DIC.
阿霉素(DOX)是一种对多种恶性肿瘤具有广谱应用的蒽环类抗生素,其临床应用受到阿霉素诱导的心脏毒性(DIC)的限制。圣草酚(ERD)已显示出心脏保护作用,但其对DIC的保护作用机制尚不清楚。
本研究旨在探讨ERD对DIC具有保护作用的潜在机制。
从中药系统药理学数据库与分析平台(TCMSP)、中药靶点预测平台(PharmMaper)、瑞士靶点预测数据库(SwissTargetPrediction)、靶点网络数据库(TargetNet)、中药系统生物学数据库(BATMAN)、基因卡片数据库(GeneCards)和药物基因组学知识库(PharmGKB)中识别ERD和DIC靶点。从基因表达综合数据库(GEO)中提取DIC与正常组织之间的差异基因表达数据。使用STRING平台构建ERD-DIC交叉靶点的蛋白质-蛋白质相互作用(PPI)网络,并用Cytoscape 3.10.0软件进行可视化。对ERD-DIC交叉靶点进行基因本体(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。验证包括使用AutoDock Tools软件进行分子对接和使用Gromacs 2019.6软件进行分子动力学模拟。
网络药理学分析揭示了43个ERD-DIC交叉靶点,包括6个关键靶点。GO功能富集分析表明,交叉靶点在550个生物学过程、45个细胞成分和41个分子功能中富集。KEGG通路富集分析确定了114条富集的信号通路。分子对接显示ERD与6个关键靶点以及ROS通路中的多个靶点具有很强的结合亲和力。分子动力学模拟表明ERD与3个关键靶点具有良好的结合。
系统的网络药理学分析表明,ERD可能通过多个靶点和途径减轻DIC,其中ROS途径可能起关键作用。这些发现为ERD治疗DIC的基础研究和临床应用提供了参考。